• Je něco špatně v tomto záznamu ?

The Effects of Selected Sesquiterpenes from Myrica rubra Essential Oil on the Efficacy of Doxorubicin in Sensitive and Resistant Cancer Cell Lines

M. Ambrož, P. Matoušková, A. Skarka, M. Zajdlová, K. Žáková, L. Skálová,

. 2017 ; 22 (6) : . [pub] 20170620

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17030726

β-caryophyllene oxide (CAO), α-humulene (HUM), trans-nerolidol (NER) and valencene (VAL) are constituents of the essential oil of Myrica rubra (MEO), which has significant antiproliferative effect in various cancer cell lines. In the present study, we compared the antiproliferative effect of these sesquiterpenes alone and in combination with the cytostatic drug doxorubicin (DOX) in cancer cell lines with different sensitivity to DOX. Two ovarian cancer cell lines (sensitive A2780 and partly resistant SKOV3) and two lymphoblast cancer cell lines (sensitive CCRF/CEM and completely resistant CEM/ADR) were used. The observed effects varied among sesquiterpenes and also differed in individual cell lines, with only VAL being effective in all the cell lines. A strong synergism of DOX with NER was found in the A2780 cells, while DOX acted synergistically with HUM and CAO in the SKOV3 cells. In the CCRF/CEM cells, a synergism of DOX with CAO and NER was observed. In resistant CEM/ADR cells, sesquiterpenes did not increase DOX efficacy, although they significantly increased accumulation of DOX (up to 10-times) and rhodamine-123 (substrate of efflux transporter ABCB1) within cancer cells. In conclusion, the tested sesquiterpenes were able to improve DOX efficacy in the sensitive and partly resistant cancer cells, but not in cells completely resistant to DOX.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030726
003      
CZ-PrNML
005      
20171030134112.0
007      
ta
008      
171025s2017 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules22061021 $2 doi
035    __
$a (PubMed)28632185
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Ambrož, Martin $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Heyrovského 1203, 50005 Hradec Králové, Czech Republic. ambrozm@faf.cuni.cz. $7 gn_A_00005430
245    14
$a The Effects of Selected Sesquiterpenes from Myrica rubra Essential Oil on the Efficacy of Doxorubicin in Sensitive and Resistant Cancer Cell Lines / $c M. Ambrož, P. Matoušková, A. Skarka, M. Zajdlová, K. Žáková, L. Skálová,
520    9_
$a β-caryophyllene oxide (CAO), α-humulene (HUM), trans-nerolidol (NER) and valencene (VAL) are constituents of the essential oil of Myrica rubra (MEO), which has significant antiproliferative effect in various cancer cell lines. In the present study, we compared the antiproliferative effect of these sesquiterpenes alone and in combination with the cytostatic drug doxorubicin (DOX) in cancer cell lines with different sensitivity to DOX. Two ovarian cancer cell lines (sensitive A2780 and partly resistant SKOV3) and two lymphoblast cancer cell lines (sensitive CCRF/CEM and completely resistant CEM/ADR) were used. The observed effects varied among sesquiterpenes and also differed in individual cell lines, with only VAL being effective in all the cell lines. A strong synergism of DOX with NER was found in the A2780 cells, while DOX acted synergistically with HUM and CAO in the SKOV3 cells. In the CCRF/CEM cells, a synergism of DOX with CAO and NER was observed. In resistant CEM/ADR cells, sesquiterpenes did not increase DOX efficacy, although they significantly increased accumulation of DOX (up to 10-times) and rhodamine-123 (substrate of efflux transporter ABCB1) within cancer cells. In conclusion, the tested sesquiterpenes were able to improve DOX efficacy in the sensitive and partly resistant cancer cells, but not in cells completely resistant to DOX.
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a doxorubicin $x farmakologie $x terapeutické užití $7 D004317
650    _2
$a mnohočetná léková rezistence $x účinky léků $7 D018432
650    _2
$a synergismus léků $7 D004357
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a lidé $7 D006801
650    _2
$a Myrica $x chemie $7 D031641
650    _2
$a oleje prchavé $x chemie $7 D009822
650    _2
$a akutní lymfatická leukemie $x farmakoterapie $7 D054198
650    _2
$a seskviterpeny $x farmakologie $7 D012717
655    _2
$a časopisecké články $7 D016428
700    1_
$a Matoušková, Petra $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Heyrovského 1203, 50005 Hradec Králové, Czech Republic. matousp7@faf.cuni.cz.
700    1_
$a Skarka, Adam $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradecká 1285, 50003 Hradec Králové, Czech Republic. adam.skarka@uhk.cz.
700    1_
$a Zajdlová, Martina $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Heyrovského 1203, 50005 Hradec Králové, Czech Republic. m.zajdlova@gmail.com.
700    1_
$a Žáková, Kateřina $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Heyrovského 1203, 50005 Hradec Králové, Czech Republic. Katerina.zakova@gmail.com.
700    1_
$a Skálová, Lenka $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Heyrovského 1203, 50005 Hradec Králové, Czech Republic. lenka.skalova@faf.cuni.cz.
773    0_
$w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 22, č. 6 (2017)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28632185 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171030134201 $b ABA008
999    __
$a ok $b bmc $g 1254319 $s 991753
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 22 $c 6 $e 20170620 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace